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Background: Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients, health care systems
and society due to increasing incidence and poor survival rates. In recent years, advances in the treatment of
metastatic NSCLC have resulted from the introduction of targeted therapies. However, the application of these new
agents increases treatment costs considerably. The objective of this article is to review the economic evidence of
targeted therapies in metastatic NSCLC.
Methods: A systematic literature review was conducted to identify cost-effectiveness (CE) as well as cost-utility
studies. Medline, Embase, SciSearch, Cochrane, and 9 other databases were searched from 2000 through April 2013
(including update) for full-text publications. The quality of the studies was assessed via the validated Quality of
Health Economic Studies (QHES) instrument.
Results: Nineteen studies (including update) involving the MoAb bevacizumab and the Tyrosine-kinase inhibitors
erlotinib and gefitinib met all inclusion criteria. The majority of studies analyzed the CE of first-line maintenance and
second-line treatment with erlotinib. Five studies dealt with bevacizumab in first-line regimes. Gefitinib and
pharmacogenomic profiling were each covered by only two studies. Furthermore, the available evidence was of
only fair quality.
Conclusion: First-line maintenance treatment with erlotinib compared to Best Supportive Care (BSC) can be
considered cost-effective. In comparison to docetaxel, erlotinib is likely to be cost-effective in subsequent treatment
regimens as well. The insights for bevacizumab are miscellaneous. There are findings that gefitinib is cost-effective in
first- and second-line treatment, however, based on only two studies. The role of pharmacogenomic testing needs to be
evaluated. Therefore, future research should improve the available evidence and consider pharmacogenomic profiling as
specified by the European Medicines Agency. Upcoming agents like crizotinib and afatinib need to be analyzed as well.
Keywords: Non-small cell lung cancer, Monoclonal antibody, Bevacizumab, Erlotinib, Gefitinib, Crizotinib, Afatinib,
Targeted therapy, Health economics, Cost-effectiveness analysis, Cost-utility analysis, Tyrosine kinase inhibitorsBackground
Lung cancer is one of the most common cancers in the
world and accounts for 12.7% of all new cancers in 2008
[1]. The high world incidence of lung cancer is expected
to increase in the next decades, particularly in countries
with medium standards due to adoption of unhealthy
western lifestyles such as smoking [2].* Correspondence: al@ivbl.uni-hannover.de
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unless otherwise stated.Non-small cell lung cancer (NSCLC) accounts for about
9 out of 10 cases of all lung cancers [3]. The survival rate
for patients with NSCLC is markedly influenced by the
stage at diagnosis [4]. At initial diagnosis approximately
25% of patients have regional metastasis and 55% of pa-
tients have already developed distant metastasis due to the
high vascularization and rich supply of lymphatic vessels
of the lung [5]. This is a reason, why lung cancer is consid-
ered the most common cause of death from cancer (18.2%
of all cancer related deaths) [1].
Surgery in combination with adjuvant chemotherapy is
a potentially curative option in early-stage disease. Iftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lange et al. BMC Pulmonary Medicine 2014, 14:192 Page 2 of 11
http://www.biomedcentral.com/1471-2466/14/192patients are not eligible for surgery, radiation therapy
combined with chemotherapy is a treatment alternative.
In patients with metastatic disease, platinum-based che-
motherapy with carboplatin or cisplatin has been consid-
ered the main treatment option for decades [6]. However,
survival rates for lung cancer patients, especially when
they have developed metastasis, are quite poor.
More recently, advances in the treatment of NSCLC
have resulted from the addition of targeted anti-cancer
drugs to chemotherapy. These targeting agents aim to
inhibit the tumor growth by interfering with specific
proteins (cell signaling) involved in tumor progression,
e.g. by blocking the signal transduction through Epider-
mal Growth Factor Receptor (EGFR), Vascular Endothelial
Growth Factor (VEGF) or Anaplastic Lymphoma Kinase
(ALK) gene.
Currently approved targeted agents for the treatment
of advanced NSCLC are the VEGF antibody bevacizu-
mab; erlotinib and gefitinib (all targeting EGFR) as well
as crizotinib targeting ALK. Another EGFR tyrosine kin-
ase inhibitors, Afatinib, is currently under review at the
European Medicine Agency (EMA) and US Food and
Drug Administration (FDA). Originally, Merck KGaA
sought to get approval by EMA for its EGFR antibody
cetuximab for the treatment of NSCLC. However, in
September 2012, the company withdrew its application
[7]. An overview of the targeted agents for the treatment
of metastatic NSCLC and the current FDA and EMA
approval status is provided in Table 1.
Despite the potential benefit of targeted agents in the
treatment of NSCLC, their application is discussed con-
troversial due to their high prices [8]. Hence, it is neces-
sary to assess the economic impact of the use of these
agents in NSCLC. Moreover, health economic evalua-
tions are necessary to support price negotiations as well
as reimbursement decisions.
The objective of this article is therefore to review and
assess the economic evidence of treatments with targeted
agents in advanced NSCLC. A systematic literature review
was conducted to identify and analyze cost-effectiveness
analysis (CEA) and cost-utility analysis (CUA) studies that
used modelling approaches. The quality of the studies was
assessed via a validated assessment tool.
Method
Prior to the systematic literature research, PICO (Popu-
lation – Indication – Comparator – Outcome) elements
were defined according to the objective of this review
(see Table 2).
A systematic literature search in AMED, BIOSIS Pre-
views, Cochrane Central Register of Controlled Trials,
Cochrane Database of Systematic Reviews, DAHTA-
Datenbank, Database of Abstracts of Reviews of Effects,
EMBASE, EMBASE Alert, Health Technology AssessmentDatabase, MEDLINE, NHS Economic Evaluation Data-
base, SciSearch and SOMED database was conducted in
September 2012 using the meta-database of the German
Institute for Medical Documentation and Information
(DIMDI). The search process was repeated again in April
2013 in order to keep the review up to date. The full-text
search included publications published in English and
German during 2000 to 2012. The following search terms
(English and German) were used and finally combined
with AND: (i) ({non small cell lung OR non small cell
bronchial OR non small lung OR non small bronchial OR
nsclc} AND {cancer OR carcinom? OR tumour OR neo-
plasm?}); (ii) (stadium IIIb OR stadium IV OR stadium 3b
OR stadium 4 OR stage IIIb OR stage Iv OR stage 3b OR
stage 4 OR metasta? OR advanced); (iii) (cetuximab OR
gefitinib OR bevacizumab OR erlotinib OR crizotinib
OR afatinib); (iv) (Cost OR Cost? OR efficien?). The “?”
was used as a wild card to represent any number of char-
acters. In addition, a hand search was conducted. (Note:
The search algorithm reveals that we included the EGFR-
antibody cetuximab in our search terms. This is due to the
fact that the withdrawal of Merck KGaA occurred after the
first data extraction in September 2012. Nevertheless, we
did not consider cetuximab in the final assessment).
Titles and abstracts of all identified publications were
reviewed independently by two researchers. Only ori-
ginal studies published in a full text were included. The
eligibility of the studies for the review was also assessed
independently. Disagreements were settled through dis-
cussion. Figure 1 summarizes the search process.
We collected data for each included article across a
range of elements, including e.g. authors, journal, study
question, population, intervention, setting, perspective
and, funding source (see Additional file 1).
Results in terms of incremental costs, cost-effectiveness
ratios and cost-utility ratios were converted to US dollars
at the exchange rate prevalent in the year of publication to
ensure comparability [9].
The Quality of Health Economic Studies (QHES) instru-
ment was used to evaluate the quality of the included
studies (Table 3) [10]. QHES is a validated instrument de-
signed to measure the quality of health economic analyses.
Each study was scored in 16 items for quality between 0
and 100, whereby 0 represents lowest quality and 100
highest quality. Each item has a weighted point value that
was generated from regression analysis. No partial points
per item are intended [10]. After summing-up points for
the 16 items the studies are grouped by the following
quartiles: (1) extremely poor quality (0–24); (2) poor qual-
ity (25–49); (3) fair quality (50–74); and (4) high quality
(75–100) [11].
The QHES evaluation was conducted independently
by two researchers. Question 3 was interpreted as mean-
ing that a justification for the choice of data must be
Table 1 Targeted agents for the treatment of metastatic NSCLC
Generic drug
name
Target Approved
population
Type EMA approved treatment regimens in NSCLC FDA approved treatment regimens in NSCLC
Afatinib EGFR EGFR positive
NSCLC patients
Tyrosine-kinase inhibitor Under review Under review
Bevacizumab VEGF All NSCLC
patients
Recombinant humanized
monoclonal antibody
In addition to platinum-based chemotherapy for
first-line treatment of adult patients with unresectable
advanced, metastatic or recurrent NSCLC other than
predominantly squamous cell histology (Aug 2007)
Non-squamous NSCLC, with carboplatin and paclitaxel for first line
treatment of unresectable, locally advanced recurrent or metastatic
disease (Oct 2006)
Cetuximab EGFR Chimeric monoclonal
IgG1 antibody
None; Merck KGaA withdrew its application formally in
Sep 2012
-
Crizotinib ALK ALK positive
NSCLC patients
Anaplastic lymphona
kinase inhibitor
Adult patients with previously treated ALK-positive NSCLC
(Oct 2012)
Patients with locally advanced or metastatic NSCLC that is
ALK-positive as detected by an FDA-approved test (Aug 2011)
Erlotinib EGRF EGFR positive
NSCLC patients
Tyrosine-kinase inhibitor Patients with locally advanced or metastatic NSCLC
after failure of at least one prior chemotherapy
regimen (Oct 2005)
• Treatment of patients with locally advanced or metastatic NSCLC
after failure of at least one prior chemotherapy regimen (Nov 2004)
• Maintenance treatment of patients with locally advanced or
metastatic NSCLC whose disease has not progressed after four
cycles of platinum-based first-line chemotherapy (April 2010)
• First-line treatment of metastatic NSCLC patients whose tumors
have epidermal growth factor receptor (EGFR) exon 19 deletions
or exon 21 (L858R) substitution mutations (May 2013)
Monotherapy for the continued treatment of patients with locally
advanced or metastatic NSCLC after failure of both platinum-based
and docetaxel chemotherapies who are benefiting or have benefited
(May 2003). The approval was limited to cancer patients who, in the
opinion of their treating physician, are currently benefiting, or have
previously benefited, from gefitinib treatment (Jun 2005)
Gefitinib EGFR EGFR positive
NSCLC patients
Tyrosine-kinase inhibitor Adult patients with locally advanced or metastatic
NSCLC with activating mutations of EGFR (Jun 2009)
(Status as of May 2013).
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Table 2 Review objective and PICO elements
Review objective The objective of this article is to review
the economic evidence of treatment of
NSCLC with targeted agents.
Participants Studies of participants diagnosed with
NSCLC. Studies were not restricted
based on age of the participants or
treatment lines.
Interventions/Comparison Studies about treatments with
approved targeted agents or agents
still going through the approval
process. The review is not limited to
specific comparators
Outcomes ICER, e.g. cost per QALY or cost per
life year gained/saved
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randomized controlled trials (RCT’s) without any justifi-
cation of choice, e.g. by a systematic literature review,
was categorized as not sufficient. The price years for the
measurement of costs were not stated occasionally and
in case associated with item 9.Results
The database search identified 407 records, 153 of them
were duplicates. After titles and/or abstract screening of
the remaining 254 records, 178 publications were ex-
cluded because they did not cover any relevant eco-
nomic content. 76 full text articles were assessed for
eligibility. Inclusion criteria were fulfilled by 16 articles
(Figure 1). Three additional records were identified by a
subsequent database search in April 2013.Figure 1 Flow diagram of articles identified and evaluated based onAll in all, 19 studies were included in the assessment.
All publications vary regarding a plurality of elements,
particularly country setting, treatment combinations and
treatment line. Table 4 provides a detailed summary of
the results of the identified CEA und CUA.
Erlotinib vs. BSC or chemotherapy
Eleven studies analyzed the cost-effectiveness of the
treatment with erlotinib compared to BSC or chemo-
therapy [12-22]: One study focused on first-line treat-
ment [16], three on first-line maintenance treatment
[13-15] and seven studies on subsequent treatment lines
[12,17-22]. Wang et al. [16] analyzed the cost-effectiveness
of first-line erlotinib monotherapy compared to carboplatin-
gemcitabine combination therapy in patients with advanced
EGFR mutation-positive NSCLC. They conclude that erloti-
nib is cost-effective from the perspective of the Chinese
health care system. However, their ICER calculation is
based on differences in progression free survival (PFS).
Vergnenegre et al. [13] estimated the cost-effectiveness of
first-line maintenance treatment with erlotinib vs. BSC in
a German, France and Italian setting. The authors con-
clude that erlotinib is cost-effective in first-line mainten-
ance therapy at a time horizon of five years. Restricting
patients to those with EGFR wild type, Walleser et al. [14]
also assessed the cost-effectiveness of first-line mainten-
ance treatment with erlotinib over a lifetime horizon. They
deduce cost-effectiveness of erlotinib for the country set-
tings of UK, Germany, France and Italy. Klein et al. [15]
focused on the cost-effectiveness of first-line maintenance
therapy with pemetrexed from a US payer perspective;
however, the authors have also considered erlotinib ininclusion criteria.
Table 3 The QHES instrument
Questions Points Yes No
1. Was the study objective presented in a clear, specific, and measurable manner? 7
2. Were the perspective of the analysis (societal, third-party payer, etc.) and reasons for its selection stated? 4
3. Were variable estimates used in the analysis from the best available source (i.e., randomized control trial - best, expert
opinion - worst)?
8
4. If estimates came from a subgroup analysis, were the groups prespecified at the beginning of the study? 1
5. Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity analysis to cover a range
of assumptions?
9
6. Was incremental analysis performed between alternatives for resources and costs? 6
7. Was the methodology for data abstraction (including the value of health states and other benefits) stated? 5
8. Did the analytic horizon allow time for all relevant and important outcomes? Were benefits and costs that went
beyond 1 year discounted (3% to 5%) and justification given for the discount rate?
7
9. Was the measurement of costs appropriate and the methodology for the estimation of quantities and unit costs
clearly described?
8
10. Were the primary outcome measure(s) for the economic evaluation clearly stated and did they include the major
short-term, long-term, and negative outcomes?
6
11. Were the health outcomes measures/scales valid and reliable? If previously tested valid and reliable measures were
not available, was justification given for the measures/scales used?
7
12. Were the economic model (including structure), study methods and analysis, and the components of the numerator
and denominator displayed in a clear, transparent manner?
8
13. Were the choice of economic model, main assumptions, and limitations of the study stated and justified? 7
14. Did the author(s) explicitly discuss direction and magnitude of potential biases? 6
15. Were the conclusions/recommendations of the study justified and based on the study results? 8
16. Was there a statement disclosing the source of funding for the study? 3
Total Points 100
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erlotinib causes lower costs and lower efficacy when com-
pared to pemetrexed at a time horizon of three years.
These results applied to patients with nonsquamous and
patients with squamous and nonsquamous histology.
Therefore, no ICER was calculated. Furthermore, the re-
ported values indicate that erlotinib is hardly cost-effective
when compared to BSC in patients with metastatic non-
squamous NSCLC.
Araújo et al. [17] analyzed erlotinib in subsequent
treatment lines versus docetaxel, pemetrexed, and BSC
for the Portuguese health care system. They conclude
that erlotinib is dominant with lower cost and higher ef-
ficacy than docetaxel as well as pemetrexed. However,
the ICER per QALY compared to BSC was $ 236,924.
Carlson et al. [12] drew a similar conclusion concerning
erlotinib vs. docetaxel or pemetrexed for a US setting.
Erlotinib seems to be dominant, since more QALYs were
gained at lower costs. The cost-effectiveness of erlotinib
vs. docetaxel was also analyzed for the setting of the Na-
tional Health Service (NHS). Lewis et al. [18] concluded
that erlotinib is dominant and cost-effective. In contrast,
Thongprasert et al. [19] and Cromwell et al. [20] did not
reveal cost-effectiveness for erlotinib vs. docetaxel for
the Thai and Canadian setting, respectively. Two yearscosts were higher with only slightly better efficacy for er-
lotinib in the second-line treatment of advanced NSCLC
patients from a Thai payer perspective [19]. However,
Cromwell et al. [20] did not discover statistical difference
in terms of costs and overall survival (OS) for the second-
line treatment with erlotinib. The cost-effectiveness of er-
lotinib vs. BSC was assessed somewhat opposing in the
studies by Cromwell et al. [21] and Bradbury et al. [22] for
the Canadian setting. Cromwell et al. [21] revealed a po-
tential cost-effectiveness of erlotinib for the third-line
treatment compared to BSC. By contrast, Bradbury et al.
[22] reported no cost-effectiveness of erlotinib for second
and third-line treatment due to a substantial lower benefit
in terms of OS. However, they calculated an increasing ef-
fectiveness of erlotinib when the analysis was restricted to
a second-line treatment setting.
Gefitinib vs. chemotherapy
Only two studies were identified that evaluated the cost-
effectiveness of gefitinib [19,23]. Zhu et al. [23] consid-
ered EGFR mutation status in their cost-effectiveness
model for first-line gefitinib maintenance therapy. Only
patients with EGFR mutation-positive NSCLC received
gefitinib. They concluded that gene-guided gefitinib
maintenance treatment is indicated as a cost-effective
Table 4 Summary of the included publications
Author
(Publication year)
Country/perspective
(Pharma sponsored?)
Treatment
line
Treatment Incremental
costs
LYG
gained
QALY’s
gained
ICER
(per LYG)
ICER
(per QALY)
In US-$ In US-$ In US-$
Erlotinib vs. BSC/chemotherapy
Wang et al. (2013) [16] China/health care
system (no)
First Erlotinib vs. carboplatin-gemcitabine
chemotherapy
$ 48,119*** 0.84 0.58 $ 30,455 $ 85,927
Vergnenegre et al. (2012) [13] France/payer (yes) First
maintenance
Erlotinib plus BSC vs. BSC 11,140 € ($ 15,476*) 0.28 39,783 € ($ 55,266*)
Germany/payer (yes) 13,141 € ($ 18,255*) 0.28 46,931 € ($ 65,196*)
Italy/payer (yes) 7,808 € ($ 10,847*) 0.28 27,885 € ($ 38,738*)
Walleser et al. (2012) [14] UK/payer (no) First
maintenance
Erlotinib vs. BSC 7,898 € ($ 10,460*) 0.39 20,711 € ($ 27,430*)
Germany/payer (no) 9,580 € ($ 12,688*) 25,124 € ($ 33,275*)
France/payer (no) 8,873 € ($ 11,752*) 23,271 € ($ 30,821*)
Spain/payer (no) 8,488 € ($ 11,242*) 22,261 € ($ 29,483*)
Italy/payer (no) 8,149 € ($ 10,793*) 21,368 € ($ 28,300*)
Klein et al. (2010) [15] USA/payer (yes) First
maintenance
Erlotinib vs. pemetrexed $ -24,474 −0.1629 no statement
Erlotinib vs. BSC $ 7,470 0.0982 $ 76,069**
Araújo et al. (2008) [17] Portugal/health care
system (yes)
Subsequent Erlotinib vs. BSC 10,366 € ($ 15,184) 0.15 0.064 70,424 € ($ 103,159) 161,742 €
($ 236,924)
Erlotinib vs. docetaxel −2,784 € ($ −4,078) 0 0.025 Dominant Dominant
Erlotinib vs. pemetrexed −6,284 € ($ −9,205) 0 0.009 Dominant Dominant
Carlson et al. (2008) [12] USA/payer (yes) Subsequent Erlotinib vs. docetaxel $ −2,127 0.01 Dominant
Erlotinib vs. pemetrexed $ −6,782 0.01 Dominant
Lewis et al. (2010) [18] UK/NHS (yes) Subsequent
(second)
Erlotinib vs. docetaxel £ −226 ($ −352) 0.032 Dominant
Thongprasert et al.
(2012) [19]
Thailand/payer (yes) Subsequent Erlotinib vs. docetaxel $ 1,746 0.0140 $ 124,703
Cromwell et al. (2011) [20] Canada/health
care system (no)
Subsequent Erlotinib vs. docetaxel 2,891 CAD ($ 2,529) 0.003 Not calculated, no
statistical differences
Cromwell et al. (2012) [21] Canada/health
care system (no)
Subsequent Erlotinib vs. BSC 11,102 CAD ($ 9,712) 0.25 36,838 CAD ($ 32,226)
Bradbury et al. (2010) [22] Canada/health
care system (no)
Subsequent Erlotinib vs. BSC 12,303 CAD ($ 11,454) 0.13 94,638 CAD ($ 88,109)
Gefitinib vs. chemotherapy
Zhu et al. (2013) [23] China/health
care system (no)
First Gefitinib (WT patients only) vs.
routine care
$ 26,150 0.74 0.46 $ 35,337 $ 57,066
Thongprasert et al. (2012) [19] Thailand/payer (yes) Subsequent Gefitinib vs. docetaxel $ -247 / 0.0140 / Dominant
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Table 4 Summary of the included publications (Continued)
Erlotinib (various combinations)
Chouaid et al. (2012) [24] France/payer (yes) First Erlotinib followed by docetaxel and
gemcitabine (DG) vs. DG followed by
erlotinib (fit elderly patients)
3,954 € ($ 5,497) / −0.01 / 395,400 €
($ 549,700)
Chouaid et al. (2013) [25] France/payer (yes) First Erlotinib followed by gemcitabine vs.
gemcitabine followed by erlotinib
(frail elderly patients)
130€ ($ 181) / −0.02 / /
Carlson et al. (2009) [26] USA/societal (no) Subsequent EGFR protein expression test
(erlotinib if high expression/docetaxel
if low expression) vs. No testing
(erlotinib monotherapy)
$ 6,274 / 0.04 / $ 179,612
EGFR gene copy number test
(erlotinib if high number/docetaxel if
low number) vs. No testing
(erlotinib monotherapy)
$ 9,209 0.12 0.06 $ 78,367 $ 162,018
Bevacizumab (plus chemotherapy)
vs. chemotherapy
Giuliani et al. (2010) [27] Italy/payer (yes) First Bevacizumab plus cisplatin and
gemcitabine vs. pemetrexed
plus cisplatin
4,007 € ($ 5,566) 0.12 34,919 € ($ 48,509)
Ahn et al. (2011) [28] Korea/payer (yes) First Bevacizumab plus cisplatin and
gemcitabine vs. cisplatin
plus pemetrexed
$ 33,322 1.10 $ 30,318
Taiwan/payer (yes) First Bevacizumab plus cisplatin and
gemcitabine vs. cisplatin
plus pemetrexed
$ 64,541 1.19 $ 54,317
Goulart et al. (2011) [29] USA/payer (no) First Bevacizumab plus
carboplatin-paclitaxel vs.
carboplatin-paclitaxel
$ 71,620 0.23 0.13 $ 308,982 $ 559,610
Klein et al. (2009) [30] USA/payer (yes) First Carboplatin/paclitaxel/
bevacizumab vs.
cisplatin/pemetrexed
$ 24,528 0.0727 0.0244 $ 337,179 $ 1,006,065
Klein et al. (2010) [15] USA/payer (yes) First Bevacizumab vs. pemetrexed $ 9,187 −0.0480 Dominated
Abbreviations: BSC best supportive care, CAD Canadian dollar, ICER incremental cost-effectiveness ratio, LYG life-year gained, QALY quality-adjusted life year, UK United Kingdom, vs. versus, WT wild type.
*Price year assumed **Not calculated by the authors ***Stated by the authors. The components of nominator and denominator, however, indicate that erlotinib is dominant.
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http://www.biomedcentral.com/1471-2466/14/192option compared to routine follow-up in China. From a
Thai payer perspective, Thongprasert et al. [19] revealed
that gefitinib is dominant compared to docetaxel in the
second-line treatment without taking pharmacogenomic
profiling into consideration.
Erlotinib (various combinations)
Three other studies addressed the cost-effectiveness of
treatments including erlotinib [24-26]. The objective of a
study by Chouaid et al. [24] was to assess the cost-
effectiveness of erlotinib followed by chemotherapy after
disease progression, compared to the reverse strategy
from the perspective of the French health care system.
Chemotherapy included docetaxel and gemcitabine.
They focused on a highly specific population of fit eld-
erly; no significant differences in patient outcomes were
identified. However, first-line treatment with chemother-
apy was slightly more expensive. Chouaid et al. [25] rep-
licated this study design for frail elderly patients and,
once again, could not detect meaningful differences in
terms of cost-effectiveness. Carlson et al. [26] evaluated
the cost-utility of implementing epidermal growth factor
receptor (EGFR) testing before initiating second-line
therapy with erlotinib. Two testing strategies were com-
pared. The EGFR protein expression test and the EGFR
gene copy number test. Within the testing strategies, er-
lotinib was given to patients with high expression or a
high copy number and docetaxel to those with low ex-
pression or a low number, respectively. Erlotinib mono-
therapy, without testing, was used as the comparator.
The analysis showed that EGFR testing has the potential
to improve quality-adjusted life expectancy in NSCLC.
However, the improvement could only be achieved at
high costs and the results had a high uncertainty.
Bevacizumab (plus chemotherapy) vs. chemotherapy
Five studies evaluated the cost-effectiveness of bevacizu-
mab in the first-line treatment of advanced non-squamous
NSCLC [15,27-30]. Four of these studies compared beva-
cizumab plus chemotherapies to chemotherapies alone
[27-30]. Giuliani et al. [27] analyzed bevacizumab in com-
bination with cisplatin and gemcitabine vs. pemetrexed
in combination with cisplatin. They conclude that the
bevacizumab-based therapy can be considered as cost-
effective in Italy. Comparing the same treatment regimens
for the Korean and Taiwanese setting, Ahn et al. [28] re-
vealed similar results. Both, Ahn et al. [28] as well as
Giuliani et al. [27], used an indirect comparison to obtain
efficacy data since no head-to-head trials existed. How-
ever, the results of both studies were completely different
in terms of LYG. Goulart et al. [29] assessed the cost-
effectiveness of bevacizumab plus chemotherapy compared
to chemotherapy alone for the US setting. Chemothera-
peutic agents were carboplatin and paclitaxel. Theyconcluded that bevacizumab is not cost-effective when
added to chemotherapy; neither when considering
LYG nor when taking QALY’s into account. The cost-
effectiveness of bevacizumab added to carboplatin and
paclitaxel in comparison to pemetrexed plus cisplatin
was further analyzed by Klein et al. [30]. Marginal benefits
in terms of LYG and QALY’s can only be achieved at very
high costs. Hence, bevacizumab based treatment is sup-
posed to be not cost-effective. Beyond, Klein et al. [15]
concluded that bevacizumab monotherapy is dominated
by pemetrexed in the first-line maintenance treatment due
to lower efficacy and higher costs.
Quality assessment (QHES)
The results of the quality assessment using the QHES
instrument are presented in Table 5. The table shows
how often each criterion was met by the 19 studies. The
quality of the included studies is at a fair level (Mean
QHES Score: 66.5 SD: 17.2). More than 40% of the stud-
ies are classified as high quality and almost half of the
studies are of fair quality. Only two studies are classified
as poor quality [24,25].
The study objectives as well as the perspective of
the analysis are clearly presented by all studies (Question
1 & 2). Only three studies [20-22] justify the data selection
e.g. through a systematic literature review. The remaining
studies may not have used data from the best available
source (Question 3). As mentioned before, using data
from RCT without any justification was not considered
appropriate. Klein et al. [15] used data from a subgroup
analysis, which, however, the authors do not describe
properly (Question 4). Uncertainty is not handled suffi-
ciently by more than half of the studies (Question 5)
[13,15,18-21,24,25,27,30]. Conducting probabilistic sensi-
tivity analysis usually fulfilled this criterion. All studies
perform an incremental analysis, since this was an inclu-
sion criterion for this review. However, Klein et al. [15,30]
do not undertake a full incremental analysis between
all available comparators (Question 6). Detailed infor-
mation on the methods used to derive data or parts of
the data is not reported in eight studies (Questions 7)
[13,15,19,23-25,27,30]. All studies handle time horizons
and discounting correctly, except for Klein et al. [30]
who do not discount in the base case as well as Chouaid
et al. [24,25] who do not discount nor clarify the time
horizon of their model (Question 8). The costs were not
measured appropriately in two thirds of the publications
(Question 9) concerning the statement of the price year
[13,14,28,30], inclusion of all relevant costs [13,24,27], de-
scription of the estimation of quantities [15,26,30], and de-
tails on expert panels [17-19]. In seven studies it remains
unclear if all long term costs were included (Question 10),
due to no consideration of subsequent treatment costs
[13,16,22,29], overall insufficient reporting [24,25], and
Table 5 Results of the QHES assessment
Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Score
Wang et al. (2013) [16] √ √ x √ √ √ √ √ √ x x √ √ x x √ 65
Vergnenegre et al. (2012) [13] √ √ x √ x √ x √ x x √ √ x x √ √ 51
Walleser et al. (2012) [14] √ √ x √ √ √ √ √ x √ x √ x x √ x 61
Klein et al. (2010) [15] √ √ x x x x x √ x √ √ √ √ x √ √ 57
Araújo et al. (2008) [17] √ √ x √ √ √ √ √ x √ √ x √ x x √ 62
Carlson et al. (2008) [12] √ √ x √ √ √ √ √ √ √ √ √ √ √ √ √ 92
Lewis et al. (2010) [18] √ √ x √ x √ √ √ x √ √ x √ x √ √ 61
Thongprasert et al. (2012) [19] √ √ x √ x √ x √ x √ √ √ √ x √ x 61
Cromwell et al. (2011) [20]* √ √ √ √ x √ √ √ √ √ √ n.a. n.a. √ √ √ 76
Cromwell et al. (2012) [21]* √ √ √ √ x √ √ √ √ √ √ n.a. n.a. √ √ √ 76
Bradbury et al. (2010) [22]* √ √ √ √ √ √ √ √ √ x √ n.a. n.a. √ √ √ 79
Zhu et al. (2013) [23] √ √ x √ √ √ x √ √ √ √ √ x √ √ √ 80
Chouaid et al. (2012) [24] √ √ x √ x √ x x x x √ x √ x √ √ 43
Chouaid et al. (2013) [25] √ √ x √ x √ x x √ x √ x x x √ √ 44
Carlson et al. (2009) [26] √ √ x √ √ √ √ √ x x √ √ √ √ √ √ 78
Giuliani et al. (2010) [27] √ √ x √ x √ x √ x √ √ √ √ x √ √ 64
Ahn et al. (2011) [28] √ √ x √ √ √ √ √ x √ √ √ √ x √ √ 78
Goulart et al. (2011) [29] √ √ x √ √ √ √ √ √ x √ √ √ √ √ √ 86
Klein et al. (2009) [30] √ √ x √ x x x x x √ √ √ √ √ √ √ 57
Statement frequency 19 19 3 18 9 17 11 16 8 12 17 12 12 8 17 17
*No model is used in the study. Question 12 & 13 are therefore not applicable.
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[26]. The results by Walleser et al. [14] might be sensitive
to the usage of a QoL measurement, whereas Wang et al.
[16] have given no justification for using an unusual health
outcome measure (Question 11). While three studies
[16,20-22] use no economic model, the model is displayed
in an intransparent manner by three studies [18,24,25]
and the analysis reported selectively by one study [17]
(Question 12). No justification for the choice of the model
was given by four studies [13,14,23,25] (Question 13). The
direction and magnitude of potential bias is not discussed
by eleven studies [13-19,24,25,27,28] (Question 14). With
one exception, the conclusions stated by the authors are
based on the respective study results and appear to be rea-
sonable. Only Araújo et al. [17] and Wang et al. [16] seem
to have selectively reported the results of their models
(Question 15). Finally, Walleser et al. [14] as well as
Thongprasert et al. [19] do not disclosure the source of
funding for the study (Question 16).
Discussion
This is a comprehensive review that analyses the cost-
effectiveness of targeting agents in the treatment of
patients with metastatic NSCLC. There exist other sys-
tematic reviews, which deal with the efficient treatment
regimens for patients with metastatic NSCLC. However,
they focus on later lines of treatment, do not include aquality assessment, or lack of current evidence [31,32].
However, cost-effectiveness analyses aim at supporting
the decision-making process regarding pricing and reim-
bursement of new technologies in health care systems.
Seven main results were derived:
(1) The majority of studies indicate a cost-effectiveness
of erlotinib compared to BSC in the first-line mainten-
ance treatment of NSCLC. However, the results for sub-
sequent treatment lines are ambiguous and do not allow
firm conclusions to be drawn. (2) Three studies show a
dominance of erlotinib when compared to docetaxel in
subsequent-line settings. Thongprasert et al. [19], how-
ever, report no cost-effectiveness for patients with meta-
static NSCLC. (3) The insights regarding bevacizumab
in the first-line treatment of advanced non-squamous
NSCLC are miscellaneous. Some studies indicate a po-
tential cost-effectiveness [27,28], whereas others report a
very high ICER [15,29,30]. (4) The evidence indicates a
possible cost-effectiveness of gefitinib, regardless of pa-
tients EGFR mutation status [19,23]. Nevertheless, these
results are based on only two studies. (5) Pharmacoge-
nomic profiling is only considered by two studies [23,26].
One study indicates that testing might not be cost-
effective prior to the treatment with erlotinib [26] whereas
another study shows that gene-guided gefitinib mainten-
ance treatment is potentially cost-effective [23]. Hence, no
final conclusion can be drawn. (6) No evidence was found
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nomic analysis of the treatment with crizotinib and afatinib
(7) The review discloses that the available evidence is of only
fair quality; particularly when compared to other economic
studies in the field of cancer [33]. However, only the results
by Araújo et al. [17] appear to have been reported selectively
to favor a medication.
Besides these main findings, the review shows a need
for further research. Future studies should clarify the
cost-effectiveness of erlotinib in subsequent treatment
lines based on efficacy data from meta-analysis or med-
ical reviews. Moreover, only one study exists that ana-
lyses the cost-effectiveness of the recently approved
first-line treatment with erlotinib. The reliability of the
results by Wang et al. [16], in addition, is limited. In
terms of data validity, further cost-effectiveness analyses
are also necessary for the treatment with bevacizumab.
Additionally, only poor evidence exists for the treatment
with gefitinib. Due to the EMA approval, further re-
search should focus on the cost-effectiveness in all lines
for the treatment of NSCLC with activating mutations of
EGFR-tyrosine kinase [34]. Thereby, it is important to
meet the international health economics standards when
evaluations are conducted. Hence, the validity of the re-
sults is more reliable. Our quality assessment revealed
that there are some criterions that are often not met.
Particularly the plausible selection of data, the handling
of uncertainty, the measurement of costs as well as the
discussion of the direction and magnitude of potential
biases were partly insufficient. Future research should
take the standards more into account.
In addition, due to the rising importance of pharmaco-
genomic profiling in the pharmaceutical treatment of
metastatic NSCLC, EGFR and ALK testing should also
be considered in future models for the treatment with
erlotinib and crizotinib, respectively. In general, the eco-
nomic consequences are not to be foreseen. On the one
hand, pharmacogenomic testing generates additional
diagnostic costs for health care systems; on the other
hand, it may reduce treatment costs due to a better re-
sponse to these targeted agents. However, there is a lack
of standard modeling techniques used in health eco-
nomic evaluations for biomarker and diagnostic tests, as
a recent review by Frank et al. [35] has shown in the
case of metastatic colorectal cancer. Hence, further re-
search should focus on clinical and economic evidence
supporting pharmacogenomic profiling prior to the ad-
ministration of targeted therapies in NSCLC.
There are limitations that need to be acknowledged
regarding the present review. Systematic reviews are dif-
ferent from traditional narrative reviews or expert com-
mentaries. They are transparent, rigorous and replicable
[36]. However, other criteria that can influence policy
making, including public opinion and expert advice,need to be considered. Systematic reviews do not equate
meta-analysis but intend to reveal the best available evi-
dence. Therefore, the literature search in the present re-
view was conducted in many different databases and was
updated shortly before the completion of this manu-
script. In addition, it must be considered that there
could be a publication bias which influences the available
evidence. This problem may be particularly important
here, since most studies are sponsored by stakeholders.
Due to the ongoing research and development in the field
of cancer the approval states are subject to frequent
changes. Therefore the results of some studies included
here are not valid for the present drug’s approval states.
Furthermore, the results of the quality assessment in
this review should be considered with caution due to the
subjective character. Two researches performed the as-
sessment independently to minimize the subjectivity of
the assessment. Afterwards the results were compared
and discussed if differences in the assessment occurred.
Additionally, the quality of the studies was assessed
using the CHEC Instrument [37]. Both instruments are
not directly comparable since the CHEC instrument
does not involve the allocation of points. The trend of
the assessment, however, was compared. No meaningful
differences were apparent. However, there are quality as-
pects which have recently gained importance, e.g. if in-
direct comparison methods are used, and which the
above mentioned instruments do not consider.
Conclusion
All in all, this review underlines the high economic im-
pact of targeted therapies in the treatment of NSCLC. A
general conclusion regarding the cost-effectiveness of
targeted therapies, however, cannot and should not be
drawn, since the results depend on the concrete medica-
tion, the treatment line, the setting and the potential ap-
plication of tests.
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